Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR).-Reference-Cited by-同舟云学术

Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR).

Published:2014-05-20 Issue:15_suppl Volume:32 Page:8117-8117
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Yoshioka Hiroshige¹,Mitsudomi Tetsuya²,Morita Satoshi³,Yatabe Yasushi⁴,Negoro Shunichi⁵,Okamoto Isamu⁶,Seto Takashi⁷,Satouchi Miyako⁸,Tada Hirohito⁹,Hirashima Tomonori¹⁰,Asami Kazuhiro¹¹,Katakami Nobuyuki¹²,Takada Minoru¹³,Shibata Kazuhiko¹⁴,Kudoh Shinzoh¹⁵,Shimizu Eiji¹⁶,Saito Hiroshi¹⁷,Toyooka Shinichi¹⁸,Nakagawa Kazuhiko¹⁹,Fukuoka Masahiro²⁰,

Affiliation:

1. Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan

2. Kinki University Faculty of Medicine, Osaka-Sayama, Japan

3. Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan

4. Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan

5. Department of Medical Oncology, Hyogo Cancer Center, Akashi, Japan

6. Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan

7. Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan

8. Department of Thoracic Oncology, Hyogo Cancer Center, Akashi, Japan

9. Department of General Thoracic Surgery, Osaka City General Hospital, Osaka, Japan

10. Department of Thoracic Malignancy, Osaka Prefectural Hospital Organization Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan

11. National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan

12. Division of Pulmonary Medicine, Kobe City Medical Center General Hospital, Kobe, Japan

13. Koyo Hospital, Wakayama, Japan

14. Department of Medical Oncology, Koseiren Takaoka Hospital, Takaoka, Japan

15. Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Osaka, Japan

16. Division of Medical Oncology and Molecular Respirology, Tottori University, Tottori, Japan

17. Department of Respiratory Medicine, Aichi Cancer Center Aichi Hospital, Okazaki, Japan

18. Department of Thoracic Surgery, Clinical Genomic Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan

19. Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan

20. Cancer Center, Izumi Municipal Hospital, Osaka, Japan

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2014.32.15_suppl.8117

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis;JTO Clinical and Research Reports;2022-05

2. Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients;Medicina;2021-11-16

3. Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data;OncoTargets and Therapy;2021-08

4. A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study;Journal of Oncology Pharmacy Practice;2021-06-13

5. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer;Cochrane Database of Systematic Reviews;2021-03-18